MX2023014197A - Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas. - Google Patents
Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas.Info
- Publication number
- MX2023014197A MX2023014197A MX2023014197A MX2023014197A MX2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A MX 2023014197 A MX2023014197 A MX 2023014197A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- group
- carboxylic acid
- neurodegenerative diseases
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211313P | 2021-06-16 | 2021-06-16 | |
| PCT/US2022/033523 WO2022266162A1 (en) | 2021-06-16 | 2022-06-15 | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014197A true MX2023014197A (es) | 2024-01-18 |
Family
ID=82595041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014197A MX2023014197A (es) | 2021-06-16 | 2022-06-15 | Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11919879B2 (enExample) |
| EP (1) | EP4355729A1 (enExample) |
| JP (1) | JP2024522718A (enExample) |
| KR (1) | KR20240021883A (enExample) |
| CN (1) | CN117500785A (enExample) |
| AR (1) | AR126159A1 (enExample) |
| AU (1) | AU2022291768A1 (enExample) |
| BR (1) | BR112023023420A2 (enExample) |
| CA (1) | CA3217423A1 (enExample) |
| IL (1) | IL308122A (enExample) |
| MX (1) | MX2023014197A (enExample) |
| TW (1) | TW202317534A (enExample) |
| WO (1) | WO2022266162A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240021883A (ko) * | 2021-06-16 | 2024-02-19 | 셀진 코포레이션 | 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물 |
| US20260209203A1 (en) * | 2022-12-16 | 2026-07-23 | Celgene Corporation | Heterocyclic Compounds as Modulators of S1P5 |
| CN121399098A (zh) | 2023-06-30 | 2026-01-23 | 赛诺菲 | 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法 |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2026119962A1 (en) | 2024-12-04 | 2026-06-11 | Syngenta Crop Protection Ag | Novel phenyl carboxamide compounds |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO167087C (no) | 1985-10-25 | 1991-10-02 | Secr Defence Brit | Fremgangsmaate for fremstilling av en nitratester. |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| DE69616366T2 (de) | 1995-09-01 | 2002-07-04 | Upjohn Co | Phenyloxazolidinone mit einer c-c-bindung zu 4-8 gliedrigen heterocyclen |
| WO2000005214A2 (en) | 1998-07-24 | 2000-02-03 | Pfizer Inc. | Isoquinolines as urokinase inhibitors |
| US6821998B2 (en) | 2001-08-30 | 2004-11-23 | Chemocentryx, Inc. | Arylamines as inhibitors of chemokine binding to US28 |
| AU2003249937A1 (en) | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| ATE496024T1 (de) | 2002-12-20 | 2011-02-15 | Merck Sharp & Dohme | 1-(amino)indane als edg-rezeptoragonisten |
| CA2509406C (en) | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2007109330A2 (en) * | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1p receptor modulating compounds |
| CA2668070A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| WO2010056788A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| WO2011036889A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| CA2800578A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors |
| CN103221404B (zh) * | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CN104271568B (zh) | 2012-05-09 | 2016-05-04 | 硕腾服务有限责任公司 | 作为抗寄生虫剂的氮杂环丁烷衍生物 |
| AR092348A1 (es) | 2012-07-11 | 2015-04-15 | Hoffmann La Roche | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
| EA201590953A1 (ru) | 2012-11-16 | 2015-08-31 | Бристол-Майерс Сквибб Компани | Пирролидиновые модуляторы gpr40 |
| JP2016533375A (ja) | 2013-10-17 | 2016-10-27 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用 |
| KR20160100407A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제의 저해제 |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| DK3140296T3 (en) | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| WO2016040225A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators |
| US11219625B2 (en) | 2015-07-24 | 2022-01-11 | Yale University | Inhibitors of N-linked glycosylation and methods using same |
| FI3362445T3 (fi) | 2015-10-12 | 2023-03-21 | Chong Kun Dang Pharmaceutical Corp | Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus |
| WO2017131149A1 (ja) * | 2016-01-29 | 2017-08-03 | 小野薬品工業株式会社 | テトラヒドロナフタレン誘導体 |
| PT3426243T (pt) | 2016-03-09 | 2021-08-19 | Raze Therapeutics Inc | Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos |
| WO2017205425A1 (en) | 2016-05-24 | 2017-11-30 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| JP7365332B2 (ja) | 2017-08-07 | 2023-10-19 | ジョイント・ストック・カンパニー “バイオキャド” | Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物 |
| WO2019141803A1 (en) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| CN113039181B (zh) | 2018-08-16 | 2024-08-13 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 |
| AU2019321588C1 (en) | 2018-08-17 | 2026-05-14 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
| WO2020071550A1 (ja) | 2018-10-04 | 2020-04-09 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| CN111484479B (zh) | 2019-01-25 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CN114072405A (zh) | 2019-07-03 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 杂环单酰基甘油脂肪酶(magl)抑制剂 |
| EP4019496B1 (en) * | 2019-08-20 | 2024-06-05 | ONO Pharmaceutical Co., Ltd. | Salt and crystal form of compound having agonistic activity to s1p5 receptor |
| CN112887914A (zh) * | 2019-11-30 | 2021-06-01 | 深圳市海思半导体有限公司 | 终端间定位方法及装置 |
| CN111704613B (zh) | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
| CN116685313A (zh) | 2020-12-23 | 2023-09-01 | 细胞基因公司 | 用于治疗神经变性疾病的含有茚满基的羧酸化合物 |
| KR20240021883A (ko) * | 2021-06-16 | 2024-02-19 | 셀진 코포레이션 | 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물 |
-
2022
- 2022-06-15 KR KR1020247001145A patent/KR20240021883A/ko active Pending
- 2022-06-15 MX MX2023014197A patent/MX2023014197A/es unknown
- 2022-06-15 US US17/840,876 patent/US11919879B2/en active Active
- 2022-06-15 IL IL308122A patent/IL308122A/en unknown
- 2022-06-15 JP JP2023577349A patent/JP2024522718A/ja active Pending
- 2022-06-15 EP EP22743647.4A patent/EP4355729A1/en active Pending
- 2022-06-15 CA CA3217423A patent/CA3217423A1/en active Pending
- 2022-06-15 AR ARP220101582A patent/AR126159A1/es unknown
- 2022-06-15 TW TW111122266A patent/TW202317534A/zh unknown
- 2022-06-15 CN CN202280042673.6A patent/CN117500785A/zh active Pending
- 2022-06-15 WO PCT/US2022/033523 patent/WO2022266162A1/en not_active Ceased
- 2022-06-15 BR BR112023023420A patent/BR112023023420A2/pt not_active Application Discontinuation
- 2022-06-15 AU AU2022291768A patent/AU2022291768A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,500 patent/US12552771B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3217423A1 (en) | 2022-12-22 |
| WO2022266162A1 (en) | 2022-12-22 |
| CN117500785A (zh) | 2024-02-02 |
| US20230028747A1 (en) | 2023-01-26 |
| KR20240021883A (ko) | 2024-02-19 |
| EP4355729A1 (en) | 2024-04-24 |
| US11919879B2 (en) | 2024-03-05 |
| TW202317534A (zh) | 2023-05-01 |
| JP2024522718A (ja) | 2024-06-21 |
| IL308122A (en) | 2023-12-01 |
| AR126159A1 (es) | 2023-09-27 |
| AU2022291768A1 (en) | 2023-11-30 |
| US12552771B2 (en) | 2026-02-17 |
| US20240270714A1 (en) | 2024-08-15 |
| BR112023023420A2 (pt) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004802A2 (pt) | Moduladores de il-17a e usos dos mesmos | |
| CL2020002719A1 (es) | Moduladores de nlrp3 | |
| CO2018011550A2 (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| BR112021021754A2 (pt) | Cicloalquilas substituídas como moduladoras da via de estresse integrada | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| BR112023023420A2 (pt) | Compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativas | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| BR112017006809A2 (pt) | compostos de ácido carboxílico úteis para inibir a prostaglandina e2 sintase-1 microssômica | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| CR20170187A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer | |
| BR112018067442A8 (pt) | Composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto | |
| CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
| NZ713589A (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| MX2017010037A (es) | Metodos de tratamiento de enfermedades inflamatorias. | |
| BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| MX2018014942A (es) | Métodos para tratar el síndrome de prader-willi. | |
| MX2021004134A (es) | Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. | |
| MX2021007161A (es) | Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia. | |
| MX392703B (es) | Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada. | |
| MX2019010174A (es) | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. | |
| CL2019002636A1 (es) | Agente para el control de enfermedades en plantas. |